OmniAb Showcases Breakthroughs in Antibody Engineering at AETC 2024

Innovative Advances in Antibody Engineering: OmniAb's Showcase at AETC 2024

OmniAb, Inc. demonstrates its commitment to revolutionizing therapeutic discovery at the 2024 Antibody Engineering & Therapeutics Conference (AETC) in San Diego, where it highlights its advancements in multispecific antibody design and bioinformatics. Dr. Yasmina Abdiche, the company's Vice President of Exploratory Research, presents significant innovations in creating multispecific antibodies, including CD3 T cell and next-generation NK cell engagers. Utilizing in vivo derived antibody domains and alternative scaffolds, OmniAb sets a new standard in the field, facilitating the development of highly effective therapeutic antibodies. This focus on innovative design positions OmniAb as a leader in creating antibodies with on-target specificity and broad epitope coverage.

CEO Matt Foehr emphasizes the advantages of OmniAb's technologies, which leverage naturally optimized human immune repertoires and AI-enhanced workflows for deep repertoire mining. This technology allows for the efficient identification and development of bispecific candidates, streamlining the drug development process. Foehr's insights underscore the company's proven track record of generating clinical-stage bispecifics, showcasing how these advancements can lead to more effective treatments in the pharmaceutical and biotech industries. The integration of AI into their workflows is particularly noteworthy, as it reduces the time and resources required for antibody discovery, thus accelerating the path from concept to clinical application.

The introduction of OmniHub™, a comprehensive bioinformatics platform, further highlights OmniAb's commitment to enhancing the antibody discovery process. Dr. Swetha Garimalla, Director of Computational Immunology, presents this platform, designed to improve partner experiences through scalable data transfer, advanced visualization, and a wide array of accessible tools. OmniHub™ aims to streamline workflows, making the process of antibody discovery more efficient and accessible to partners in the pharmaceutical and biotech sectors. By incorporating cutting-edge technology into their operations, OmniAb seeks to transform the landscape of therapeutic discovery and provide significant value to its collaborators.

In addition to showcasing these innovations, OmniAb's presence at AETC reinforces its dedication to advancing the field of antibody engineering. By licensing its discovery research technologies, the company empowers pharmaceutical, biotech, and academic institutions to identify optimal antibodies and binding proteins for drug development. This strategic approach not only enhances their partners' capabilities but also accelerates the overall pace of innovation in therapeutic development, ultimately benefiting patients worldwide. As OmniAb continues to push the boundaries of antibody engineering, its contributions are poised to shape the future of targeted therapies.